This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions.
Patient characteristics, safety and outcomes were collected.
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9. 01 and 15. 7 months, respectively. No unexpected adverse events were reported.
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.
Future oncology (London, England). 2015 Nov 06 [Epub ahead of print]
Annalisa Guida, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Matteo Santoni, Veronica Prati, Camillo Porta, Laura Cosmai, Donatella Donati, Cinzia Del Giovane, Pasquale Mighali, Roberto Sabbatini
Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy. , AO Santa Maria Nuova, Reggio Emilia, Italy. , Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy. , Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy. , Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti Umberto I, Ancona, Italy. , Oncologia Medica a Direzione Universitaria, Fondazione del Piemonte per l'Oncologia, Istituto per la Ricerca e Cura del Cancan Candiolo, Torino, Italy. , Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy. , Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy. , Unità Operativa Oncologia, Azienda Ospedaliero-Universitaria, Ferrara, Italy. , Statistics Unit, Department of Clinical, Diagnostic & Public Health Medicine, University of Modena & Reggio Emilia, Modena, Italy. , Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy. , Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.